Stay updated with breaking news from Genscript Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9) segment is a leading segment in terms of revenue by product type in the gene editing tools market, and accounted for an approximate revenue share of 75% in 2018.CRISPR/Cas9 gene editing tools are most widely used by scientists to create tran...
Genscript Biotech Co. (OTCMKTS:GNNSF – Get Rating) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 364,100 shares, a drop of 60.5% from the March 15th total of 922,500 shares. Based on an average daily volume of 4,400 shares, the days-to-cover ratio is presently 82.8 days. […]
Genscript Biotech Co. (OTCMKTS:GNNSF – Get Rating)’s stock price dropped 12.2% during trading on Thursday . The stock traded as low as 3.06 and last traded at 3.06. Approximately 2,000 shares traded hands during mid-day trading, a decline of 14% from the average daily volume of 2,338 shares. The stock had previously closed at 3.49. […]
According to latest research by FMI, the global gene editing tools market is estimated to have accounted for more than US$ 481.3 Mn in terms of value in 2022. The report on the gene editing tools market further projects that the gene editing tools market is likely to grow at a CAGR of over 18.8% during the period 20...
/PRNewswire/ -- The Protein A Resin Market report provides a detailed insight into the protein a resin market from 2021 to 2026 and forecasts its growth rate...